Vaccination of patients with solid tumours

Giorgio Parmiani, L. Pilla, C. Castelli, L. Rivoltini

Research output: Contribution to journalArticle

Abstract

The molecular characterisation of human tumour antigens recognised by T cells has provided new impetus for immunisation of patients bearing tumours expressing well-defined antigens. After evaluating the immunogenicity of the new, molecularly characterised antigens in vitro, several clinical studies were conducted to assess the in vivo immunogenicity and the clinical efficacy of vaccines including these antigens. The findings generated by trials based on the administration of peptides or DNA-encoding antigens are discussed to highlight the limits of this therapeutic approach; however, this approach has resulted in some complete and durable regressions, although still in a unsatisfactory small number of cases (5-25%). The recent use of dendritic cells loaded ex vivo with tumour antigens suggests that a high frequency of tumour-specific immune responses can be achieved. Possible means of overcoming the clinical limits and improving the outcome of previous studies are also discussed.

Original languageEnglish
Pages (from-to)817-824
Number of pages8
JournalAnnals of Oncology
Volume14
Issue number6
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

Vaccination
Antigens
Neoplasm Antigens
Neoplasms
Dendritic Cells
Immunization
Vaccines
Outcome Assessment (Health Care)
T-Lymphocytes
Peptides
DNA
Therapeutics

Keywords

  • Cancer
  • Melanoma
  • T cells
  • Tumour escape
  • Vaccination

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vaccination of patients with solid tumours. / Parmiani, Giorgio; Pilla, L.; Castelli, C.; Rivoltini, L.

In: Annals of Oncology, Vol. 14, No. 6, 01.06.2003, p. 817-824.

Research output: Contribution to journalArticle

Parmiani, Giorgio ; Pilla, L. ; Castelli, C. ; Rivoltini, L. / Vaccination of patients with solid tumours. In: Annals of Oncology. 2003 ; Vol. 14, No. 6. pp. 817-824.
@article{a1a3b075d76e44fdb231a3b695b23e47,
title = "Vaccination of patients with solid tumours",
abstract = "The molecular characterisation of human tumour antigens recognised by T cells has provided new impetus for immunisation of patients bearing tumours expressing well-defined antigens. After evaluating the immunogenicity of the new, molecularly characterised antigens in vitro, several clinical studies were conducted to assess the in vivo immunogenicity and the clinical efficacy of vaccines including these antigens. The findings generated by trials based on the administration of peptides or DNA-encoding antigens are discussed to highlight the limits of this therapeutic approach; however, this approach has resulted in some complete and durable regressions, although still in a unsatisfactory small number of cases (5-25{\%}). The recent use of dendritic cells loaded ex vivo with tumour antigens suggests that a high frequency of tumour-specific immune responses can be achieved. Possible means of overcoming the clinical limits and improving the outcome of previous studies are also discussed.",
keywords = "Cancer, Melanoma, T cells, Tumour escape, Vaccination",
author = "Giorgio Parmiani and L. Pilla and C. Castelli and L. Rivoltini",
year = "2003",
month = "6",
day = "1",
doi = "10.1093/annonc/mdg246",
language = "English",
volume = "14",
pages = "817--824",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Vaccination of patients with solid tumours

AU - Parmiani, Giorgio

AU - Pilla, L.

AU - Castelli, C.

AU - Rivoltini, L.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - The molecular characterisation of human tumour antigens recognised by T cells has provided new impetus for immunisation of patients bearing tumours expressing well-defined antigens. After evaluating the immunogenicity of the new, molecularly characterised antigens in vitro, several clinical studies were conducted to assess the in vivo immunogenicity and the clinical efficacy of vaccines including these antigens. The findings generated by trials based on the administration of peptides or DNA-encoding antigens are discussed to highlight the limits of this therapeutic approach; however, this approach has resulted in some complete and durable regressions, although still in a unsatisfactory small number of cases (5-25%). The recent use of dendritic cells loaded ex vivo with tumour antigens suggests that a high frequency of tumour-specific immune responses can be achieved. Possible means of overcoming the clinical limits and improving the outcome of previous studies are also discussed.

AB - The molecular characterisation of human tumour antigens recognised by T cells has provided new impetus for immunisation of patients bearing tumours expressing well-defined antigens. After evaluating the immunogenicity of the new, molecularly characterised antigens in vitro, several clinical studies were conducted to assess the in vivo immunogenicity and the clinical efficacy of vaccines including these antigens. The findings generated by trials based on the administration of peptides or DNA-encoding antigens are discussed to highlight the limits of this therapeutic approach; however, this approach has resulted in some complete and durable regressions, although still in a unsatisfactory small number of cases (5-25%). The recent use of dendritic cells loaded ex vivo with tumour antigens suggests that a high frequency of tumour-specific immune responses can be achieved. Possible means of overcoming the clinical limits and improving the outcome of previous studies are also discussed.

KW - Cancer

KW - Melanoma

KW - T cells

KW - Tumour escape

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=0038449106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038449106&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdg246

DO - 10.1093/annonc/mdg246

M3 - Article

C2 - 12796017

AN - SCOPUS:0038449106

VL - 14

SP - 817

EP - 824

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -